Compliance

 Longevity, Regenerative & Preventive Medicine

A Quick-Reference Summary for Medical Directors and Founders 

When crafting direct response marketing, patient acquisition funnels, or educational materials, promotional copy must align with global regulatory frameworks.

 Longevity and regenerative medicine face exceptional scrutiny.

To keep your digital presence compliant, ensure your marketing strategy aligns with the

 three core regulatory pillars below.

Pillar 1: Private Clinics & Service Delivery

Focuses on medical ethics, professional conduct, facility registration,

 and patient care.

  United States (US)

• State Medical Boards: While federal agencies oversee products, state medical boards (e.g., California, Texas, Florida) govern the professional conduct of physicians. Deceptive or exaggerated marketing regarding clinical outcomes constitutes professional misconduct.
• Corporate Practice of Medicine (CPOM): Longevity centers operating under a management services organization (MSO) model must ensure that clinical autonomy remains strictly with the licensed physicians, a boundary heavily monitored by the FTC Healthcare Enforcement Task Force.
• Preventive Screenings: Copy for multi-cancer early detection or full-body MRIs must not exaggerate diagnostic capabilities or induce unwarranted patient panic.

      United Kingdom (UK)

• General Medical Council (GMC): Doctors must adhere to strict ethical guidelines. Marketing copy cannot apply psychological pressure on patients, offer financial inducements, or make unprovable claims about the quality of care.
• Care Quality Commission (CQC): Private clinics offering regulated activities (e.g., diagnostic procedures, prescribing) must be registered for those specific scopes. Advertising a clinical service before the facility is CQC-registered for it is an immediate violation.

    European Union (EU)

• National Medical Orders: Clinic marketing is decentralized and governed by national medical codes (e.g., Ordre des Médecins in France, Bundesärztekammer in Germany, EOF in Greece). Most EU member states maintain highly restrictive rules regarding the commercialization and public promotion of medical services.

Pillar 2: MedTech & HealthTech

Focuses on Software as a Medical Device (SaMD), diagnostic tools, wearables,

 and data privacy.

 United States (US)

• FDA Classifications: If your platform, AI tool, or longevity app claims to diagnose, treat, or predict a disease, the FDA regulates it as Software as a Medical Device (SaMD). Marketing an unapproved software tool with diagnostic claims triggers swift enforcement.

  United Kingdom (UK)

• MHRA & UKCA Marking: Software used to identify longevity biomarkers, analyze biological age, or guide clinical decisions must carry the appropriate UKCA mark and comply with MHRA medical device guidelines.

   European Union (EU)

• Medical Device Regulation (MDR): The EU's MDR enforces strict rules for digital health. Most AI-driven diagnostic or risk-prediction software falls into higher-risk tiers, requiring rigorous clinical evaluation before any marketing claims can be made.
• GDPR & Biometric Data: Tracking genetic profiles, epigenetic age, or biomarkers triggers the GDPR's "Special Category Data" protections. Marketing funnels and apps must secure explicit, unambiguous, and revocable consent before processing any patient health data.

Pillar 3: Supplements, IV Therapy & Drugs

Focuses on authorized health claims, compounding restrictions, 

and direct-to-consumer advertising bans.

     United States (US)

• Nutraceuticals (DSHEA): Supplements cannot claim to "diagnose, treat, cure, or prevent any disease". Copy must use structure/function claims (e.g., "supports cellular health" instead of "reverses cellular aging" or "prevents dementia").
• IV Therapy & Regenerative Biologics: The FTC actively prosecutes clinics claiming IV vitamin cocktails or NAD+ drips can cure or prevent chronic illnesses without robust clinical trials. Furthermore, marketing unapproved stem cell or exosome therapies triggers immediate FDA warning letters.

        United Kingdom (UK)

• Prescription-Only Medicines (POMs): Under the ASA CAP Code, private clinics are strictly prohibited from advertising POMs directly to the public. This includes off-label longevity medications (e.g., metformin, rapamycin), certain hormone replacement therapies (HRT), and prescription-grade IV ingredients.
• Great Britain NHC Register: Supplement claims must strictly utilize wording approved on the official GB register. Claims implying a supplement or IV drip can treat depression, severe fatigue, or medical deficiencies are prohibited.

      European Union (EU)

• Direct-to-Consumer Advertising (DTCA) Ban: The EMA strictly prohibits advertising prescription medications directly to consumers across all member states.
• EFSA Register of Health Claims: Any longevity nutraceutical or IV formulation sold or promoted in the EU may only use health claims explicitly approved by the European Food Safety Authority (EFSA). Broad anti-aging promises like "extends lifespan" are completely unauthorized.

Official Regulatory Citations & Legal Frameworks

For deep-dive legal reviews, specific compliance text, and application guidelines, please consult the official regulatory repositories:

1. Private Clinics & Clinical Governance

• US State Medical Boards: Federation of State Medical Boards (FSMB) Policy Frameworks.
• US Clinic Enforcement: FTC Healthcare Enforcement & Antitrust Updates.
• UK Doctor Conduct: General Medical Council (GMC) Good Medical Practice Code on Advertising.
• UK Clinic Inspection: Care Quality Commission (CQC) Scope of Registration Regulations.
• EU Medical Ethics: Standing Committee of European Doctors (CPME) Ethics Charter.

2. MedTech & HealthTech Software

• US SaMD Regulations: U.S. Food and Drug Administration (FDA) Digital Health Center.
• UK MedTech Guidelines: UK Gov MHRA Regulatory Guidance for Medical Devices .
• EU MDR Guidelines: European Commission Medical Device Regulation (MDR) Software Guidelines.
• EU Data Privacy: General Data Protection Regulation (GDPR) Special Category Data Guide .

3. Supplements, IV Therapy & Substances

• US Biological Frameworks: FDA HCT/P Framework for Cellular & Tissue Products.
• US Supplement Labeling: FDA Label Claims for Food & Dietary Supplements Guide.
• US Advertising Standards: Federal Trade Commission (FTC) Health Products Compliance Guidance.
• UK Advertising Codes: ASA CAP Code Section 12: Health, Medical and Beauty.
• UK Permitted Claims: Great Britain Nutrition and Health Claims (NHC) Register.
• EU Centralized Medicines: European Medicines Agency (EMA) Marketing Authorisation Guidelines.
• EU Permitted Claims: European Commission EU Register of Health Claims 

DISCLAIMER

Educational Summary Only – Not Legal Counsel

The information provided on this page serves exclusively as a high-level educational summary of global healthcare marketing regulations (FDA, FTC, MHRA, ASA, and EMA) for longevity, regenerative, and preventive medicine. While this text is curated to assist medical directors, founders, and clinical teams in identifying potential copy vulnerabilities, it does not constitute formal legal advice, a binding regulatory audit, or a statutory compliance guarantee. Advertising frameworks change frequently; always consult your internal legal counsel or a specialized healthcare compliance attorney before deploying new public-facing copy, patient funnels, or ad campaigns.